Vistagen TherapeuticsVTGN
13F holders, Q3 2024 (September 30)At the end of Q3 2024, 47 institutions reported holding Vistagen Therapeutics Inc. (VTGN) in their 13F filings, up 5 from Q2 2024. 8 opened new positions and 3 sold out. The largest holders were TCG Crossover Management, LLC ($8.1M), BVF Inc. ($6.0M) and Vanguard Group Inc. ($5.4M). 3 famous investors held it, including Ken Griffin (0.0% of Citadel Advisors's portfolio), Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio) and Israel Englander (0.0% of Millennium Management's portfolio).
- Company
- Vistagen Therapeutics Inc.
- CUSIP
- 92840H400
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 8 | $8.9M |
| Exits | 3 | $1.1M |
All 13F filers, Q2 2024 → Q3 2024: 3,140,343 shares bought and 1,550,605 shares sold, net +1,589,738 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 47 holders
| TCG Crossover Management, LLC | 0.68% | New | 2,676,580 | $8.1M |
| BVF Inc. | 0.18% | No change | 2,000,000 | $6.0M |
| Vanguard Group Inc. | 0.00% | No change | 1,793,166 | $5.4M |
| Stempoint Capital LP | 1.47% | Reduce -0.1% | 1,846,792 | $4.9M |
| Commodore Capital LP | 0.30% | No change | 1,575,000 | $4.7M |
| Nantahala Capital Management, LLC | 0.38% | No change | 1,517,696 | $4.6M |
| Sphera Funds Management LTD. | 0.40% | No change | 808,550 | $2.4M |
| Great Point Partners LLC | 0.61% | Reduce -55.9% | 674,075 | $2.0M |
| BlackRock, Inc. | 0.00% | — | 412,129 | $1.2M |
| Citadel Advisors | 0.00% | Reduce -48.9% | 321,885 | $969K |
| Geode Capital Management, LLC | 0.00% | Reduce -10.9% | 258,524 | $778K |
| Renaissance Technologies | 0.00% | Add +193.7% | 190,600 | $574K |
| Goldman Sachs Group Inc. | 0.00% | Add +0.7% | 176,261 | $531K |
| ADAR1 Capital Management, LLC | 0.08% | New | 163,078 | $491K |
| BML Capital Management, LLC | 0.27% | No change | 150,000 | $452K |
| State Street Corp. | 0.00% | No change | 88,708 | $267K |
| Blair William & Co. | 0.00% | No change | 88,466 | $266K |
| AdvisorShares Investments LLC | 0.04% | Add +30.9% | 67,780 | $204K |
| Two Sigma Investments, LP | 0.00% | Reduce -8.8% | 61,542 | $185K |
| Susquehanna International Group, LLP | 0.00% | Reduce -20.0% | 52,094 | $157K |
| Northern Trust Corp. | 0.00% | Reduce -1.1% | 49,431 | $149K |
| Valence8 US LP | 0.05% | New | 34,376 | $103K |
| American Century Companies Inc. | 0.00% | Reduce -0.4% | 30,197 | $91K |
| Squarepoint Ops LLC | 0.00% | Add +142.0% | 27,575 | $83K |
| Millennium Management | 0.00% | New | 25,337 | $76K |
| Charles Schwab Investment Management Inc. | 0.00% | No change | 23,302 | $70K |
| Simplex Trading, LLC | 0.00% | Add +34.5% | 23,000 | $69K |
| HighTower Advisors, LLC | 0.00% | New | 20,828 | $64K |
| Virtu Financial LLC | 0.00% | Add +30.5% | 20,210 | $61K |
| Kestra Advisory Services, LLC | 0.00% | New | 20,033 | $60K |
| Jane Street Group, LLC | 0.00% | New | 19,659 | $59K |
| Osaic Holdings, Inc. | 0.00% | Reduce -7.3% | 10,226 | $31K |
| UBS Group AG | 0.00% | Reduce -47.5% | 10,121 | $30K |
| Morgan Stanley | 0.00% | Reduce -9.3% | 5,319 | $16K |
| Royal Bank of Canada | 0.00% | Add +316.4% | 4,501 | $14K |
| Caption Management, LLC | 0.00% | New | 4,460 | $13K |
| Cwm, LLC | 0.00% | No change | 2,416 | $7K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -9.1% | 2,259 | $7K |
| Bank of America Corp. | 0.00% | Add +660.5% | 1,810 | $5K |
| Citigroup Inc. | 0.00% | Add +40866.7% | 1,229 | $4K |
| Bfsg, LLC | 0.00% | No change | 1,000 | $3K |
| SJS Investment Consulting Inc. | 0.00% | No change | 100 | $301 |
| Jones Financial Companies LLLP | 0.00% | No change | 80 | $246 |
| Farther Finance Advisors, LLC | 0.00% | No change | 81 | $244 |
| Fairman Group, LLC | 0.00% | No change | 29 | $87 |
| FMR LLC | 0.00% | Reduce -99.4% | 25 | $75 |
| JPMorgan Chase & Co. | 0.00% | No change | 16 | $48 |
"% of holder's portfolio" is VTGN's weight in each manager's 13F, not the share of Vistagen Therapeutics Inc. the manager owns.